Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2024-520132-15-00
Authorised, recruiting Phase III

The effect of music on perioperative anxiety and pain of patients undergoing retrobulbar anaesthesia

2024-520132-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Medical University Of Graz
Sponsor type
Educational Institution
Therapeutic area
Anesthesia and Analgesia
Decision date
10/11/2025
Enrollment target
240
Sites
Austria

Condition studied

Patients undergoing vitrectomy and/or cataract surgery

Investigational medicinal product(s)

Nervenruh forte - DrageesBromazepam Genericon 3 mg Filmtabletten

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

NRS-P score 30 seconds after retrobulbar block.

Endpoint detail

STAI Questionnaire at admission; NRS-P and NRS-A before retrobulbar injection; NRS-P score 30 seconds after retrobulbar block; NRS-P and NRS-A score directly after operation; Speed rate/duration of retrobulbar injection

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520132-15-00 on CTIS ↗ ← All trials in the EU